Drugs / lactase
lactase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01145339 | Jul → Nov 2011 | lactose intolerance | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07784062 | Nov 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT07088302 Comparator | Aug 2025 → Feb 2026 overdue | congenital lactase deficiency, nutritional disorder | Alexandria University | Recruiting | No outcome recorded |
| — | NCT05100719 Comparator | Sep 2022 → Sep 2026 overdue | irritable bowel syndrome, lactose intolerance | University of Pecs | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01145339 ↗ |
| Known as | Beta-galactosidase (aspergillus) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108505 ↗ |
| Known as | G9S0VV191I | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108505 ↗ |
| Known as | Lactase enzyme | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07784062 ↗ |
| Action | Restore | “lactase/beta-galactosidase enzyme replacement” NCT05100719 ↗ |
| Modality | Protein / enzyme biologic | “lactase/beta-galactosidase enzyme replacement” NCT05100719 ↗ |
| Route | Other | “receive enteral feeds treated with lactase enzyme” NCT07784062 ↗ |